<DOC>
	<DOCNO>NCT00069953</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy paclitaxel , fluorouracil , cisplatin use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell PURPOSE : This phase II trial study well combination chemotherapy follow chemoradiotherapy , without surgery , work treat patient resectable locally advanced cancer esophagus gastroesophageal junction .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Chemoradiotherapy , With Without Surgery , Treating Patients With Resectable Locally Advanced Cancer Esophagus Gastroesophageal Junction</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility treatment paclitaxel , cisplatin , fluorouracil follow chemoradiotherapy possible surgical salvage patient resectable locally advanced carcinoma esophagus gastroesophageal junction . - Determine overall disease-free survival patient treat regimen . - Determine treatment-related toxicity regimen patient . - Determine tolerance surgical salvage patient treat regimen . - Determine morbidity mortality surgical salvage patient treat regimen . OUTLINE : This multicenter study . - Induction therapy : Patients receive fluorouracil ( 5-FU ) IV continuously 96 hour begin day 1 29 ; cisplatin IV 1 hour day 1-5 29-33 ; paclitaxel IV 2 hour day 1 29 ; pegfilgrastim subcutaneously ( SC ) day 6 34 OR filgrastim ( G-CSF ) SC day 6-15 34-42 . Treatment continue absence unacceptable toxicity . - Chemoradiotherapy : Patients receive cisplatin IV 1 hour day 57-61 5-FU IV continuously day 57-61 , 64-68 , 71-75 , 78-82 , 85-89 , 92-96 . Patients concurrently undergo external beam radiotherapy day 57-61 , 64-68 , 71-75 , 78-82 , 85-89 , 92-96 . Patients residual recurrent esophageal disease 4-6 week completion chemoradiotherapy may undergo salvage esophagectomy . Patients follow periodically . PROJECTED ACCRUAL : A total 42 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma adenocarcinoma esophagus gastroesophageal junction Primary ( nonrecurrent ) disease Amenable resection Stage great T1 , N0 endoscopic ultrasound Must entirely confine esophagus gastroesophageal junction periesophageal soft tissue Tumor may extend 2 cm stomach No multiple primary carcinoma esophagus No cervical esophageal carcinoma tumor less 5 cm cricopharyngeus No evidence disseminate cancer Suggestion liver metastases positron emission tomography must prove negative biopsy image study Palpable supraclavicular node must negative cancer biopsy Bronchoscopy require lesion less 26 cm incisor exclude tracheoesophageal fistula invasion No celiac adenopathy great 2 cm PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute granulocyte count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hemoglobin least 10 g/dL Hepatic Not specify Renal Creatinine great 1.5 mg/dL AND/OR Creatinine clearance least 65 mL/min Calcium great 11 mg/dL Cardiovascular No uncontrolled heart disease No uncontrolled hypertension Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able comprehend study requirement consider likely comply study parameters No malignancy within past 5 year except curable nonmelanoma skin cancer carcinoma situ cervix No uncontrolled diabetes No hypersensitivity E. coliderived product PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 5 year since prior systemic chemotherapy Endocrine therapy Not specify Radiotherapy No prior chest upper abdomen radiotherapy Surgery No prior esophageal gastric surgery Other No concurrent photodynamic therapy No concurrent investigational agent esophageal carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>